Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
CURRICULUM VITAE Kimberly C. Claeys, PharmD, BCPS Assistant Professor Infectious Diseases Department of Pharmacy Practice and Science University of Maryland School of Pharmacy 20 N Pine Street, Baltimore, MD 21201 Office: N432 Phone: 410.706.3215 Fax: 410.706.6580 Email: [email protected] ACADEMIC & PROFESSIONAL APPOINTMENTS 03/2016 – present Assistant Professor Department of Pharmacy Practice and Science University of Maryland School of Pharmacy Baltimore, MD 07/2016 – present Antimicrobial Stewardship Pharmacist University of Maryland Medical Center Baltimore, MD EDUCATION & PROFESSIONAL TRAINING 07/2013 – 05/2015 Graduate Certificate in Public Health School of Medicine, Department of Family Medicine and Public Health Sciences Wayne State University Detroit, MI 07/2013 – 02/2016 Post-Doctoral Infectious Diseases Health Outcomes Fellowship Anti-Infective Research Laboratory Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit, MI Program Director: Michael J. Rybak, PharmD, MPH 07/2012 – 07/2013 ASHP-Accredited PGY1 Pharmacy Residency University of Illinois at Chicago College of Pharmacy Chicago, IL Program Director: Frank P. Paloucek, PharmD, DABAT 09/2008 – 05/2012 Doctor of Pharmacy Eugene Applebaum College of Pharmacy and Health Sciences Wayne State University Detroit, MI LICENSURE 04/2016 – present Maryland Department of Health and Mental Hygiene Registered Pharmacist License No. 24048 09/2012 – present Illinois Department of Financial and Professional Regulation Registered Pharmacist License No. 051296192 CERTIFICATION 09/2015 – present Antimicrobial Stewardship Certificate Program Society of Infectious Diseases Pharmacist Pending completion 11/2013 – present Board Certified Pharmacotherapy Specialist Board of Pharmacy Specialties 07/2012 – 07/2013 Resident Teaching Certificate University of Illinois at Chicago College of Pharmacy 09/2008 – 05/2012 Pharmacy-Based Immunization Delivery American Pharmacists Association PROFESSIONAL MEMBERSHIP National Associations 08/2014 – present Infectious Diseases Society of America 12/2013 – present European Society of Clinical Microbiology and Infectious Diseases 07/2013 – present Society of Infectious Diseases Pharmacists 07/2013 – present American Society for Microbiology 04/2011 – present American College of Clinical Pharmacy 12/2010 – present American Society of Health-System Pharmacists 08/2007 – 05/2012 American Pharmacists Association - Academy of Student Pharmacists State & Local Associations 04/2016 – present Maryland Society of Health-System Pharmacists 07/2012 – 07/2013 Illinois Council of Health-System Pharmacists 12/2010 – 05/2012 Phi Lambda Sigma Leadership Society, Gamma Chi Chapter 04/2010 – 05/2012 Rho Chi Academic Honors Society, Alpha Chi Chapter 09/2008 – 09/2012 Michigan Pharmacist Association INSTITUTIONAL SERVICE University of Maryland School of Pharmacy, Baltimore, MD 04/2016 – present Residency Research Committee 04/2016 – present Pharmacotherapy Pathway Committee – Doctor of Pharmacy Program Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI 09/2015 Early Academic Admissions Interviewer – Doctor of Pharmacy Program 06/2015 – 01/2016 Faculty Search Committee – Pharmacoepidemiology Faculty Position KC Claeys CV Page 2 of 12 AWARDS & RECOGNITION 04/2015 Making a Difference in Infectious Disease (MAD-ID) Travel Grant 06/2014 54th Interscience Conference on Antimicrobial Agents and Chemotherapy Infectious Disease Fellows Grant Program 02/2014 24th Annual European Congress of Clinical Microbiology and Infectious Diseases Travel Grant 06/2013 University of Illinois at Chicago College of Pharmacy Richard A. Hutchinson Award for Excellence in Pharmacy Practice 05/2012 Eugene Applebaum College of Pharmacy and Health Sciences Pharmacy Awards and Honors Convocation Award for Outstanding Professional and Community Service 05/2012 Eugene Applebaum College of Pharmacy and Health Sciences Pharmacy Awards and Honors Convocation Natural Standard Research Collaboration Award 11/2011 Southeastern Michigan Society of Health-System Pharmacists Student Research Award 10/2011 Eugene Applebaum College of Pharmacy and Health Sciences 8th Annual Research Forum Student Poster Award for Clinical Research 02/2011 Michigan Pharmacists Association Good Government Award 05/2011, 05/2010, 11/2009 Eugene Applebaum College of Pharmacy and Health Sciences John Helfman Pharmacy Merit Scholarship LEADERSHIP EXPERIENCE 09/2013 – 09/2014 Society of Infectious Diseases Pharmacists Political Advocacy Committee 03/2011 – 03/2012 American Pharmacists Association – Academy of Student Pharmacists National Policy Standing Committee 02/2011 Michigan Pharmacists Association Annual Convention and Exhibition Delegate for Wayne State University/House of Delegates Credentialing Committee 10/2010 – 05/2011 Phi Lambda Sigma Leadership Society – Gamma Chi Chapter Charter member and member of the Nominations Committee 04/2010 – 04/2011 Student Society of Health-System Pharmacists – Wayne State University Wayne State University Chapter, Member of Charter Board of Directors 10/2009 – 03/2011 American Pharmacists Association – Academy of Student Pharmacists Wayne State University Chapter, Student Political Advocacy Network Chair KC Claeys CV Page 3 of 12 PHARMACY PRACTICE EXPERIENCE University of Maryland Medical Center, Baltimore, MD 07/2016 – present Antimicrobial Management Subcommittee Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI 01/2015 – 01/2016 Antimicrobial Stewardship Committee 02/2014 – 12/2015 Infectious Diseases Consult Preceptor: Michael J. Rybak, PharmD, MPH University of Illinois at Chicago Hospital and Health Sciences System, Chicago, IL 07/2012 – 07/2013 PharmD On Call Program Preceptor: Frank P. Paloucek, PharmD, DABAT 07/2012 – 07/2013 HIV Telemedicine Clinic Preceptor: Melissa Badowski, PharmD, BCPS, AAHIVE 11/2012 – 12/2012 Infectious Diseases Consult Preceptor: Larry H. Danziger, PharmD, FIDSA TEACHING AND PRECEPTING EXPERIENCE Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI 09/2014 – 02/2016 Small Group-Based Learning Facilitator PHA 5175 Pharmacotherapeutic Problem Solving 05/2014 – 02/2016 Research Co-Preceptor FPH 8990 Master’s Project (MPH) 05/2014 – 09/2014 Research Co-Preceptor PPR 5990 Directed Study in Pharmacy Practice 01/2013 – 02/2015 Didactic Lecturer PHA 4210 Pharmacotherapy Module: Infectious Diseases Detroit Medical Center, Detroit Receiving Hospital, Detroit, MI 02/2014 – 12/2015 Clinical Preceptor Infectious Diseases Consult Rotation University of Illinois at Chicago College of Pharmacy, Chicago, IL 06/2013 Large Group-Based Learning Facilitator PHAR 357 Experiential V (Infectious Diseases) Pneumonia and Urinary Tract Infections Review 04/2013 Didactic Lecturer Pharmacy Grand Rounds Major Epidemics Through History 02/2013 Faculty Moderator PMPR 385 Case-Based Infectious Diseases MRSA, hVISA, VISA and VRSA KC Claeys CV Page 4 of 12 RESEARCH EXPERIENCE 06/2016 – present Respiratory Viral Panel (RVP) diagnostic testing utilization and association with antibiotic use among hospitalized patients Funding: None Role: Co-investigator, data generation and analysis, abstract and manuscript generation 05/2016 – present Examining the role of novel risk scoring tools in determining risk of resistant organisms in pneumonia presenting from the community: Are they better than the current HCAP criteria? Funding: None Role: Co-investigator, data generation and analysis, abstract and manuscript generation 05/2016 – present Assessing Clinical Outcomes in Colistin versus Polymyxin B Funding: None Role: Co-investigator, data generation and analysis, abstract and manuscript generation 04/2016 – present Diagnosis and Management of Complicated Urinary Tract Infections (cUTIs) Presenting from Long Term Care Facilities: What are the Standards of Care? Funding: Submitted to MAD-ID Research Network ($29,169.50) pending Role: Primary investigator primary study development, grant writer, data collection and analysis, abstract and manuscript generation 04/2016 – present Dalbavancin Treatment Pathway to Improve Clinical and Economic Outcomes in Complicated Skin and Skin Structure Infections Presenting to the Emergency Department Funding: Submitting to Allergan Plc Role: Primary investigator primary study development, grant writer, data collection and analysis, abstract and manuscript generation 03/2016 – present Improving antimicrobial stewardship by better predicting risk of multidrug resistant infection among hospitalized community-acquired and healthcare-associated pneumonia Funding: Submitted to ACCP Mentored Research Program ($50,000.00) pending Role: Primary investigator primary study development, grant writer, data collection and analysis, abstract and manuscript generation 02/2016 – present Impact of a Pharmacist-Driven Care Package on Staphylococcus aureus Bacteremia Management in a Large Community Hospital Funding: None Role: Co-Investigator, statistical analysis and manuscript generation 11/2015 – 02/2016 Use of rapid diagnostics and predictive modeling for MRSA acute bacterial skin and skin structure infections (ABSSSIs) to optimize antibiotic therapy and cost of care in the Emergency Department and Observation Unit Funding: The Urban Center for Antimicrobial Resistance Discovery Education and Stewardship (UCARDES) Program, Wayne State University ($50,000) Role: Co-primary investigator, primary study development, grant writer, data collection and analysis, abstract and manuscript generation KC Claeys CV Page 5 of 12 12/2014 – present Derivation and validation of a risk assessment tool for methicillinresistant S. aureus acute bacterial skin and skin structure infections (ABSSSIs) Funding: Bayer International ($194,645.75) Role: Co-investigator, primary grant writer and study development, data collection and analysis, assist with app development, abstract and manuscript generation 11/2014 – 02/2016 Clinical and economic outcomes of acute bacterial skin and skin structure infections (ABSSSIs): focus on those at risk for methicillin-resistant S. aureus Funding: Forest Laboratories/Actavis ($137,486.90) Role: Co-investigator, primary grant writer and study development, data collection and analysis, assist with app development, abstract and manuscript generation 10/2014 – 06/2015 Length of enterococcal bacteremia and associated clinical outcomes Funding: None Role: Co-primary investigator, primary study development, data collection and analysis, abstract and manuscript generation 09/2014 – 11/2015 Deriving a clinically useful severity scoring system in acute bacterial skin and skin structure infections (ABSSSIs) for determination of admission requirements Funding: None Role: Co-primary investigator, primary study development, data collection and analysis, abstract and manuscript generation 01/2014 – 10/2014 Improving hospital-based antimicrobial prescribing through a multisystem review of antibiotic utilization patterns Funding: Michigan Department of Community Health ($260,263.00) Role: Co-investigator, grant development, large database analysis, abstract generation 12/2013 – 07/2015 Burden of illness with acute bacterial skin and skin structure infections discharged from the emergency department or observation unit: Experience at the Detroit Medical Center Funding: None Role: Co-primary investigator, primary study development, data collection and analysis, abstract and manuscript generation 09/2013 – 07/2015 Clinical outcomes in patients with vancomycin heteroresistant S. aureus (hVISA) nosocomial lower respiratory tract infections Funding: None Role: Co-primary investigator, primary study development, data collection and analysis, abstract and manuscript generation 09/2013 – 06/2016 Patient outcomes and burden of illness of Gram-negative lower respiratory infections in intensive care units Funding: Cubist Pharmaceuticals/Merck ($151,996.80) Role: Co-investigator, primary study development, data collection and analysis, abstract and manuscript generation 08/2013 – 09/2014 Combination daptomycin and trimethoprim/sulfamethoxazole in methicillin-resistant S. aureus infections Funding: None Role: Co-primary investigator, primary study development, data collection and analysis, abstract and manuscript generation KC Claeys CV Page 6 of 12 07/2013 – 11/2015 Impact of early daptomycin versus vancomycin therapy for bloodstream infection caused by methicillin-resistant S. aureus Funding: Cubist Pharmaceuticals/Merck ($177,792.50) Role: Co-investigator, data collection and analysis, laboratory assessment of clinical isolates, abstract and manuscript generation 07/2013 – 02/2016 Prospective evaluation of clinical and economic outcomes of ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections (ABSSSIs) documented or at risk of methicillin-resistant S. aureus Funding: Forest Laboratories/Actavis ($363,815.50) Role: Co-investigator, multi-center study coordinator, account management, patient enrollment, data collection and analysis ADVISORY BOARD AND JOURNAL REVIEW 07/2015 – present Infectious Diseases and Therapy 09/2014 – present Pharmacotherapy PUBLICATIONS Manuscripts in Progress 05/2016 Claeys KC, Liao S, Danziger LH. The Past, Present, and Future of Tigecycline: What Went Wrong, What Went Right. 11/2015 Claeys KC, Zasowski EJ, Lagnf AM, Hallesy JA, Davis SL, Rybak MJ. Burden of illness of Gram-negative pneumonia treated in the intensive care unit 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Severity assessment and level of care in acute bacterial skin and skin structure infections: Utilizing predictive analytics to improve patient care 08/2015 Claeys KC, Zasowski EJ, Lagnf AM, Levine DP, Davis SL, Rybak MJ. Practical application of risk factors for MRSA Acute Bacterial Skin and Skin Structure Infections (submitted, International Journal Antimicrobial Agents) 06/2015 Claeys KC, Zasowski EJ, Lagnf AM, Nyguen CT, Nagel JL, Levine DP, Kaye KS, Davis SL, Rybak MJ. Propensity matched analysis of patients treated with vancomycin versus daptomycin for methicillin-resistant S. aureus bacteremia (submitted , Antimicrob Agents Chemother) Manuscripts in Peer-Reviewed Journals 04/2016 Lagnf AM, Zasowski EJ, Claeys KC, Casapao AM, Rybak MJ. Comparison of risk factors and outcomes associated with polymicrobial and monomicrobial enterococcal infections. Am J Infect Control. 2016 April 11; PMID: 27079241 03/2016 Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Time is of the essence: The impact of delayed antibiotic therapy on outcomes in hospital-onset enterococcal infections. Clin Infect Dis. 2016 Mar 3. PMID 26945013 01/2016 Claeys KC, Lagnf AM, Hallesy JA, Compton MT, Gravelin AL, Davis SL, Rybak MJ. Pneumonia caused by methicillin-resistant Staphylococcus aureus: Does vancomycin heteroresistance matter? Antimicrob Agents Chemother 2016 Jan 4; 60(3):1708-16. PMID: 26729497 KC Claeys CV Page 7 of 12 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Rybak MJ. Comparison of outcomes between patients with single versus multiple positive blood cultures for Enterococcus: Infection or Illusion? Am J Infect Control. 2015 Sep 18. pii: S01966553(15)00849-4. doi:10.1016/j.ajic.2015.08.002. PMID: 26388037 06/2015 Claeys KC, Lagnf AM, Patel TB, Jacob MG, Davis DL, Rybak MJ. Acute bacterial skin and skin structure infections treated with intravenous antibiotics in the emergency department or observational unit: Experience at the Detroit Medical Center. Infect Dis Ther. 2015 Jun; 4(2): 173-86. doi: 10.1007/s40121-015-00697. PMID: 26055392 03/2015 Casapao AM, Lodise TP, Davis SL, Claeys KC, Kullar R, Levine DP, Rybak MJ. Association between vancomycin day one exposure profile and outcomes among patients with methicillin-resistant Staphylococcus aureus infective endocarditis. Antimicrob Agents Chemother. 2015 Jun; 59(6): 2978-85. doi: 10.1128/AAC.03970-14. PMID: 25753631 01/2015 Claeys KC, Smith JR, Casapao AM, Mynatt RP, Avery L, Schroff A, Yamamura D, Davis SL, Rybak MJ. Impact of the combination of daptomycin and trimethoprim-sulfamethoxazole on clinical outcomes in methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 2015 Apr; 59(4): 1969-76. doi: 10.1128/AAC.04141-14. PMID: 25605354 12/2014 Claeys KC, Fiorvento AD, Rybak MJ. A review of novel combinations of colistin and lipopeptide or glycopeptide antibiotics for the treatment of multidrugresistant Acinetobacter baumannii. Infect Dis Ther 2014: 3:69–81. doi: 10.1007/s40121-014-0051-9. PMID: 25475412 04/2014 Smith JR, Claeys KC, Barber KE, Rybak MJ. High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it. Curr Infect Dis Rep. 2014 Oct; 16(10): 429. doi: 10.1007/s11908-014-0429-6. PMID: 25165017 TEXTBOOK CHAPTERS 12/2014 Smith JR, Claeys KC, Zasowski EJ, Yim J, Rybak MJ (pending publication). Daptomycin resistance in Gram-positive organisms in Kaye KS (Ed.) Antimicrobial Drug Resistance: Mechanisms of Drug Resistance. New York, New York: Springer CONTINUING EDUCATION ARTICLES 06/2015 Rybak JM, Claeys KC. Isavuconazole, a new agent for the treatment of invasive mold infections. MAD-ID 2015 June; 5(2). ACPE No. 0485-0000-15-018-H01-PA 11/2011 Claeys KC, Dodd P. Continuing Education: New and notable medications approved in 2010 and 2011. Michigan Pharmacist 2011; 49: 25. ACPE No. 112000-11-009-H01-P CONTRIBUTED CONTENT 10/2010 Interviewed for: Cobb, J. What’s Most Important? Pharmacists in Michigan Choose Top Legislative/Regulatory Issues. Michigan Pharmacist 2010; 48:6 KC Claeys CV Page 8 of 12 POSTERS & PRESENTATIONS Professional International Platform Presentations 06/2016 Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. Predictors of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) among Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infective Endocarditis (IE) [Session 436 - Epidemiology and Control of MRSA] ASM Microbe, Boston, MA 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Practical application of risk factors for methicillin-resistant Staphylococcus aureus (MRSA) in the treatment of antibacterial skin and skin structure infections (ABSSSI) [1828] 55 th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, DP Levine, KS Kaye, Rybak MJ. Propensity Matched analysis of daptomycin versus vancomycin for bloodstream infections caused by methicillin-resistant Staphylococcus aureus (MRSA) [2762] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Zasowski EJ, Claeys KC, Lagnf AM, Witt JS, Rybak MJ. Predictors of vancomycinresistant enterococci among patients with community-onset enterococcal bloodstream infections [3073] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Zasowski EJ, Claeys KC, Lagnf AM, Witt JS, Rybak MJ. Linezolid versus high-dose daptomycin for the treatment of vancomycin-resistant enterococcus bloodstream infections [3051] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA Professional International Invited Presentations 04/2015 “Developing a risk assessment tool for MRSA ABSSSI” Bayer International Global Council Meeting, Copenhagen, Denmark 04/2010 “Through patients’ eyes: Advocacy and patient care” American Pharmacist Association (APhA) Annual National Meeting – APhA Academy of Student Pharmacists, Round Table Discussion, Washington, DC Professional International & National Poster Presentations 06/2016 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Use of Intravenous versus Oral Antibiotics in the Emergency Department/Observation Unit (ED/OU) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSIs) [Friday-513] ASM Microbe, Boston, MA 06/2016 Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Predictors Of Multidrug Resistant (MDR) Pseudomonas Aeruginosa Nosocomial Pneumonia in the Intensive Care Unit (ICU) [Saturday-381] ASM Microbe, Boston, MA 04/2016 Claeys KC, Levine DP. Length of bacteraemia and mortality in S. aureus infective endocarditis [6163] 26th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands KC Claeys CV Page 9 of 12 04/2016 Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. Relationship between duration of methicillin-resistant Staphylococcus aureus bloodstream infection and mortality [P0485] 26th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands 04/2016 Zasowski EJ, Trinh TD, Claeys KC, Lagnf AM, Casapao AM, Davis SL, Rybak MJ. Ceftaroline fosamil for the treatment of methicillin-resistant Staphylococcus aureus infective endocarditis [6638] 26th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands 04/2016 Trinh TD, Zasowski EJ, Claeys KC, Lagnf AM, Davis SL, Rybak MJ. Impact of vancomycin population analysis profile (PAP) minimum inhibitory concentration (MIC) in high-inoculum methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) [P0477] 26th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Amsterdam, Netherlands 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness with Gram-negative (GN) lower respiratory infections (LRTIs) admitted to intensive care units (ICUs) [1792] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Risk Assessment and severity analysis in acute bacterial skin and skin structure infections (ABSSSIs) [1840] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Zasowski EJ, Claeys KC, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant Staphylococcus aureus pneumonia [2220] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 09/2015 Zasowski EJ, Claeys KC, Casapao AM, Sabagha N, Klinker KP, Davis SL, Rybak MJ. Ceftaroline fosamil (CPT) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) [2207] 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Diego, CA 05/2015 Claeys KC, Zasowski EJ, Lagnf AM, Davis SL, Rybak MJ. Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department (ED) or observation unit (OU): Experience at the Detroit Medical Center 18th Annual Making a Difference in Infectious Disease (MAD-ID), Orlando, FL 04/2015 Claeys KC, Lagnf AM, Gravelin A, Hallesy J, Alderson R, Davis SL, Rybak MJ. Clinical outcomes of patients with heterogeneous vancomycin-intermediate S. aureus (hVISA) lower respiratory tract infections [P0660] 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark 04/2015 Zasowski EJ, Claeys KC, K. Roberts K, Levine DP, Davis SL, Rybak MJ. Retrospective evaluation of daptomycin plus ceftaroline fosamil versus DAP plus sulfamethoxazole/trimethoprim (SMX/TMP) for methicillin-resistant Staphylococcus aureus bloodstream infections [P0700] 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark 04/2015 Claeys KC, Lagnf AM, Rybak MJ. Length of enterococcal bacteremia and associated clinical outcomes [P0038] 25th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Copenhagen, Denmark KC Claeys CV Page 10 of 12 09/2014 Claeys KC, Casapao AM, Davis DL, Rybak MJ. Burden of illness associated with acute bacterial skin and skin structure infections evaluated in the emergency department or observational unit: Experience at the Detroit Medical Center [K1702] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC 09/2014 Claeys KC, Nagel JL, Pogue JM, Casapao AM, Finks K, Neuhauser M, Schneider A, Davis SL, and Rybak MJ. Implementing the National Healthcare Safety Network’s (NHSN’s) Antimicrobial Use Option to aid in determination of resistance among key nosocomial pathogens [K-327] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC 09/2014 Nagel JL, Pogue JM, Claeys KC, Casapao AM, Finks J, Rybak MJ. Utilization of the Centers for Disease Control and Prevention National Healthcare Safety Network Antimicrobial Use and Resistance Module (CDC AUR) to compare multicenter antimicrobial use [K-332] 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC 05/2014 Claeys KC, Nagel JL, Pogue JM, Casapao AM, Davis DL, Rybak MJ. National Healthcare Safety Network’s Antibiotic Utilization and Resistance Program 17 th Annual Making a Difference in Infectious Disease (MAD-ID), Orlando, FL 05/2014 Claeys KC, Casapao AM, Pogue J, Bhatia N, Mynatt RP, Saely S, Arthur C, Welch R, Sherwin R, Hafeez W, Levine D, Kaye K, Delgado G, Giuliano CA, Talka R, Johnson LB, Davis SL, Rybak MJ. Rapid diagnostic testing with GeneXpert improves enrollment in a randomized clinical trial for detection of methicillin-resistant S. aureus in acute bacterial skin and skin structure infections [P1471] 24th European Congress of Clinical Microbiology and Infectious Disease (ECCMID), Barcelona, Spain 10/2013 Claeys KC, Casapao AM, Goeff DA, Kaye KS, Levine DP, Davis SL, Rybak MJ. Daptomycin versus vancomycin for bloodstream infection caused by methicillinresistant Staphylococcus aureus (MRSA): Preliminary results. 10th Annual Research Forum, Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, MI 12/2012 Claeys KC, Mucksavage JJ, Tesoro EP, Kim KS, Jennings KA. Effects of intraarterial verapamil on post-angiogram hemodynamics. 2012 University Health System Consortium (UHC), Las Vegas, NV 09/2011 Rhoney DH, Claeys KC, Parker D, Goodwin HE, Lewin J. National survey of drug shortages in Neurocritical Care Units (NCCU): Description of shortages with commonly used agents [S183 154] 8th Annual Neurocritical Care Society Meeting, Montreal, Canada 09/2011 Rhoney DH, Claeys KC, Parker D, Goodwin HE, Lewin J. A Multi-Centre Evaluation of the Impact of Drug Shortages in Neurocritical Care (NCCU): Management Strategies and Resource Utilization. [S189 160] 8th Annual Neurocritical Care Society Meeting, Montreal, Canada Professional National And Local Presentations 05/2015 “Skin and Skin Structure Infections: Risk assessment and decision analysis to improve clinical outcomes” Annual Infectious Diseases Fellowship Forum, Brainerd, MN 04/2014 “Impact of early daptomycin versus vancomycin in methicillin-resistant Staphylococcus aureus bacteremia” Annual Infectious Diseases Fellowship Forum, Captiva Island, FL KC Claeys CV Page 11 of 12 05/2013 “Early use of daptomycin versus vancomycin for methicillin-resistant Staphylococcus aureus bacteremia with vancomycin minimum inhibitory concentration >1 mg/L: A matched cohort study” Pharmacy Critical Care Journal Club, University of Illinois at Chicago, Chicago, IL 05/2013 “Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia” Pharmacy Critical Care Journal Club, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois 05/2013 03/2013 “Gram-negative resistance – ESBL, Amp C and KPC” Noon-Report PGY1 Pharmacy Residents and in-service to surgical intensive care residents University of Illinois at Chicago College of Pharmacy & University of Illinois Hospital & Health Sciences System, Chicago, Illinois 09/2012 “Management of status epilepticus” Pharmacy Critical Care Journal Club, University of Illinois at Chicago College of Pharmacy, Chicago, Illinois 08/2011 10/2010 “Early versus late initiation of parenteral nutrition in critically ill adults” Pharmacy Critical Care Journal Club, Detroit Receiving Hospital, Detroit, Michigan “Policy and advocacy: A student’s perspective” PPR 3020: Introduction to Patient Care Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan “Why is policy and advocacy important?” Wayne State University APhA-ASP Eugene Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan 09/2010 KC Claeys CV Page 12 of 12